| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0000800 | Intron-Exon | chr6:4817513-4892337 | chr6:4817279-4892103 | 391 nt | 0.4859 |
| hsa_CDYL_0000900 | Intron-Exon-Intron | chr6:4820861-4892613 | chr6:4820627-4892379 | 250 nt | 0.4160 |
| hsa_CDYL_0001100 | Exon-Intron | chr6:4836351-4839063 | chr6:4836117-4838829 | 118 nt | 0.5932 |
| hsa_CDYL_0001200 | Exon-Intron | chr6:4836351-4867670 | chr6:4836117-4867436 | 192 nt | 0.4688 |
| hsa_CDYL_0001300 | Exon-Exon | chr6:4836351-4892613 | chr6:4836117-4892379 | 192 nt | 0.4688 |
| hsa_CDYL_0001400 | Intron-Exon-Intron | chr6:4838946-4892613 | chr6:4838712-4892379 | 250 nt | 0.5000 |
| hsa_CDYL_0001500 | Intron-Intron | chr6:4846056-4867670 | chr6:4845822-4867436 | 81 nt | 0.3951 |
| hsa_CDYL_0001600 | Intron-Intron | chr6:4853630-4858846 | chr6:4853396-4858612 | 250 nt | 0.4560 |
| hsa_CDYL_0001800 | Intron-Intron | chr6:4854759-4864555 | chr6:4854525-4864321 | 409 nt | 0.3985 |
| hsa_CDYL_0001700 | Intron-Intron | chr6:4854759-4867670 | chr6:4854525-4867436 | 250 nt | 0.3200 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].